Suppr超能文献

德尔塔和奥密克戎变异株流行期间的 SARS-CoV-2 再感染。

SARS-CoV-2 reinfections during the Delta and Omicron waves.

机构信息

Department of Pathology, Division of Medical Microbiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

National Institute of Allergy and Infectious Disease, NIH, Bethesda, Maryland, USA.

出版信息

JCI Insight. 2022 Oct 24;7(20):e162007. doi: 10.1172/jci.insight.162007.

Abstract

BACKGROUNDIncreased SARS-CoV-2 reinfection rates have been reported recently, with some locations basing reinfection on a second positive PCR test at least 90 days after initial infection. In this study, we used Johns Hopkins SARS-CoV-2 genomic surveillance data to evaluate the frequency of sequencing-validated, confirmed, and inferred reinfections between March 2020 and July 2022.METHODSPatients who had 2 or more positive SARS-CoV-2 tests in our system, with samples sequenced as a part of our surveillance efforts, were identified as the cohort for our study. SARS-CoV-2 genomes of patients' initial and later samples were compared.RESULTSA total of 755 patients (920 samples) had a positive test at least 90 days after the initial test, with a median time between tests of 377 days. Sequencing was attempted on 231 samples and was successful in 127. Rates of successful sequencing spiked during the Omicron surge; there was a higher median number of days from initial infection in these cases compared with those with failed sequences. A total of 122 (98%) patients showed evidence of reinfection; 45 of these patients had sequence-validated reinfection and 77 had inferred reinfections (later sequencing showed a clade that was not circulating when the patient was initially infected). Of the 45 patients with sequence-validated reinfections, 43 (96%) had reinfections that were caused by the Omicron variant, 41 (91%) were symptomatic, 32 (71%) were vaccinated prior to the second infection, 6 (13%) were immunosuppressed, and only 2 (4%) were hospitalized.CONCLUSIONSequence-validated reinfections increased with the Omicron surge but were generally associated with mild infections.FUNDINGFunding was provided by the Johns Hopkins Center of Excellence in Influenza Research and Surveillance (HHSN272201400007C), CDC (75D30121C11061), Johns Hopkins University President's Fund Research Response, Johns Hopkins Department of Pathology, and the Maryland Department of Health.

摘要

背景

最近有报道称 SARS-CoV-2 再感染率有所增加,有些地方将再感染定义为初次感染后至少 90 天出现第二次阳性 PCR 检测。本研究使用约翰霍普金斯大学 SARS-CoV-2 基因组监测数据评估 2020 年 3 月至 2022 年 7 月期间测序证实、确诊和推断的再感染频率。

方法

在我们的系统中,有 2 次或更多次阳性 SARS-CoV-2 检测且样本作为我们监测工作的一部分进行测序的患者被确定为本研究的队列。将患者初始和后续样本的 SARS-CoV-2 基因组进行比较。

结果

共有 755 名(920 份样本)患者在初次检测后至少 90 天有阳性检测结果,两次检测的中位时间间隔为 377 天。对 231 份样本进行了测序,其中 127 份成功测序。在 Omicron 激增期间,成功测序的比例飙升;与测序失败的病例相比,这些病例初次感染后的中位天数更高。共有 122 名(98%)患者有再感染证据;其中 45 名患者有测序证实的再感染,77 名患者有推断的再感染(后续测序显示患者初次感染时未流行的谱系)。在 45 名有测序证实的再感染患者中,43 名(96%)由 Omicron 变体引起的再感染,41 名(91%)有症状,32 名(71%)在第二次感染前接种了疫苗,6 名(13%)有免疫抑制,只有 2 名(4%)住院。

结论

随着 Omicron 激增,测序证实的再感染增加,但通常与轻度感染相关。

资金

本研究由约翰霍普金斯大学流感研究与监测卓越中心(HHSN272201400007C)、美国疾病控制与预防中心(75D30121C11061)、约翰霍普金斯大学校长基金研究响应、约翰霍普金斯大学病理学系和马里兰州卫生署提供资助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/216b/9714778/6a7341190c6f/jciinsight-7-162007-g137.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验